Form D · Manufacturing
Gaiamer Biotechnologies, Inc.
Inglewood, CA · CIK 0001817875
Offering snapshot reported Jul 16, 2021 · SEC filing
- Reported sold
- $100K Offering amount: $5M
- Investors reported
- Not reported Form D · investor count
- Minimum accepted
- Not reported Reported outside-investor minimum
- First sale
- Not reported As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 16, 2021 | Amendment | $100,000 | No comparison | Not reported | SEC filing |
| Jul 15, 2020 | Initial | $100,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Not reported
- Exemptions
- Not reported
- Duration over one year
- Not reported
- Business combination
- Not reported
- Sales commissions
- Not reported
- Finders' fees
- Not reported
- Form D file number
- 021-371022
Source: Form D, filed Jul 16, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Charles Caliman | Director, Executive |
| Jihene Dhaouadi | Director |
| Araya Mesfin | Director |
| Christopher Sargent | Director, Executive |
| Jerry Schindler | Director |
| Keith Tinsley | Director, Executive |
| Thomas Trimbach | Director, Executive |
Issuer details
Industry: Manufacturing (See others in industry)
Address:
420 Hindry Ave. Unit A
Inglewood, CA, 90301
Inglewood, CA, 90301